{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endometrium+Cancer&page=33",
    "query": {
      "condition": "Endometrium Cancer",
      "page": 33
    },
    "page_size": 10
  },
  "pagination": {
    "page": 33,
    "page_size": 10,
    "total_count": 791,
    "total_pages": 80,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endometrium+Cancer&page=34&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endometrium+Cancer&page=32&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-26T09:56:41.377Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05827614",
      "title": "Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Triple Negative Breast Cancer (TNBC)",
        "High Grade Serous Ovarian Carcinoma",
        "High Grade Endometrial Carcinoma",
        "Anogenital Cancer",
        "Head and Neck (HNSCC)",
        "Cutaneous Squamous Cell Carcinoma (CSCC)",
        "Cervical Squamous Cell Carcinoma",
        "ER+ Breast Cancer",
        "Leiomyosarcoma (LMS)",
        "Undifferentiated Pleomorphic Sarcoma (UPS)",
        "Pancreatic Cancer Metastatic",
        "Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "BBI-355",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "Futibatinib",
          "type": "DRUG"
        },
        {
          "name": "BBI-825",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boundless Bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2023-03-24",
      "completion_date": "2026-03-17",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-10-26T09:56:41.377Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Santa Monica, California • Denver, Colorado + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05827614"
    },
    {
      "nct_id": "NCT03660826",
      "title": "Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometrial Adenocarcinoma",
        "Endometrial Mixed Cell Adenocarcinoma",
        "Endometrial Serous Adenocarcinoma",
        "Endometrial Undifferentiated Carcinoma",
        "Endometrioid Adenocarcinoma",
        "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspirate",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Capivasertib",
          "type": "DRUG"
        },
        {
          "name": "Cediranib Maleate",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 288,
      "start_date": "2018-09-27",
      "completion_date": "2027-07-01",
      "has_results": true,
      "last_update_posted_date": "2026-10-22",
      "last_synced_at": "2026-10-26T09:56:41.377Z",
      "location_count": 760,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 481 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03660826"
    },
    {
      "nct_id": "NCT02824328",
      "title": "A Pilot Study Investigating the Effect of Chemotherapy on the Tumoral Immunoprofile of Gynecologic Cancers",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Peritoneal Cancer",
        "Uterine Endometrial Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 47,
      "start_date": "2016-06",
      "completion_date": "2022-01-10",
      "has_results": false,
      "last_update_posted_date": "2022-02-11",
      "last_synced_at": "2026-10-26T09:56:41.377Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02824328"
    },
    {
      "nct_id": "NCT03138408",
      "title": "SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "SC-004",
          "type": "DRUG"
        },
        {
          "name": "ABBV-181",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 24,
      "start_date": "2017-06-14",
      "completion_date": "2019-05-02",
      "has_results": false,
      "last_update_posted_date": "2019-05-14",
      "last_synced_at": "2026-10-26T09:56:41.377Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Duarte, California + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03138408"
    },
    {
      "nct_id": "NCT02552121",
      "title": "Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovary Cancer",
        "Cervix Cancer",
        "Endometrium Cancer",
        "Bladder Cancer",
        "Prostate Cancer (CRPC)",
        "Esophagus Cancer",
        "Lung Cancer (NSCLC)"
      ],
      "interventions": [
        {
          "name": "Tisotumab vedotin (HuMax-TF-ADC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2015-11-30",
      "completion_date": "2017-12-13",
      "has_results": true,
      "last_update_posted_date": "2021-04-08",
      "last_synced_at": "2026-10-26T09:56:41.377Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02552121"
    },
    {
      "nct_id": "NCT04576104",
      "title": "Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia",
        "Endometrial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Extended Release Metformin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Megestrol Acetate",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2021-11-29",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-21",
      "last_synced_at": "2026-10-26T09:56:41.377Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Denver, Colorado • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Winfield",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04576104"
    },
    {
      "nct_id": "NCT00027690",
      "title": "Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Uterine Corpus Carcinoma"
      ],
      "interventions": [
        {
          "name": "Gefitinib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 56,
      "start_date": "2002-06",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2019-07-23",
      "last_synced_at": "2026-10-26T09:56:41.377Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00027690"
    },
    {
      "nct_id": "NCT05194072",
      "title": "A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Neoplasms",
        "Peritoneal Neoplasms",
        "Fallopian Tube Neoplasms",
        "Triple Negative Breast Neoplasms",
        "HER2 Negative Breast Neoplasms",
        "Hormone Receptor Positive Breast Neoplasms",
        "Endometrial Neoplasms",
        "Carcinoma, Non-Small-Cell Lung",
        "Cholangiocarcinoma",
        "Gallbladder Carcinoma",
        "Adenoid Cystic Carcinoma"
      ],
      "interventions": [
        {
          "name": "Felmetatug Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen, a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2022-01-12",
      "completion_date": "2025-05-14",
      "has_results": false,
      "last_update_posted_date": "2026-01-09",
      "last_synced_at": "2026-10-26T09:56:41.377Z",
      "location_count": 22,
      "location_summary": "Aurora, Colorado • Denver, Colorado • Celebration, Florida + 9 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05194072"
    },
    {
      "nct_id": "NCT00295945",
      "title": "Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cervical Cancer",
        "Endometrial Cancer",
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Pain",
        "Perioperative/Postoperative Complications",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "fentanyl citrate",
          "type": "DRUG"
        },
        {
          "name": "hydromorphone hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "ropivacaine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 240,
      "start_date": "2005-03",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2014-05-20",
      "last_synced_at": "2026-10-26T09:56:41.377Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00295945"
    },
    {
      "nct_id": "NCT00019331",
      "title": "Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Endometrial Cancer",
        "Head and Neck Cancer",
        "Liver Cancer",
        "Lung Cancer",
        "Melanoma (Skin)",
        "Pancreatic Cancer",
        "Testicular Germ Cell Tumor",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ras peptide cancer vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DetoxPC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1997-10",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2013-06-20",
      "last_synced_at": "2026-10-26T09:56:41.377Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00019331"
    }
  ]
}